Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price cut by investment analysts at Wells Fargo & Company from $145.00 to $136.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 47.07% from the company’s previous close.

Other analysts have also recently issued reports about the company. Citizens Jmp boosted their price target on Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the stock a “market outperform” rating in a research report on Friday. Citigroup reaffirmed an “outperform” rating on shares of Rhythm Pharmaceuticals in a report on Friday, December 12th. Oppenheimer downgraded shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada initiated coverage on shares of Rhythm Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $145.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $150.00 target price on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $133.71.

Rhythm Pharmaceuticals Trading Down 5.7%

NASDAQ:RYTM traded down $5.60 during trading hours on Friday, reaching $92.47. 313,298 shares of the company were exchanged, compared to its average volume of 650,791. The firm has a market cap of $6.17 billion, a PE ratio of -29.95 and a beta of 2.00. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20. The stock’s 50-day moving average is $104.28 and its 200-day moving average is $103.50.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. The business had revenue of $57.25 million during the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. The company’s quarterly revenue was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.72) earnings per share. As a group, research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 3,350 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. This represents a 13.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,003 shares of company stock worth $2,589,015 in the last quarter. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its holdings in Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC raised its position in Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Rhythm Pharmaceuticals by 1,110.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after buying an additional 322 shares during the period. Optiver Holding B.V. boosted its stake in shares of Rhythm Pharmaceuticals by 65.2% in the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after buying an additional 144 shares during the period. Finally, SBI Securities Co. Ltd. grew its position in shares of Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after buying an additional 145 shares in the last quarter.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Analysts at Citizens Jmp raised their price target to $176 and kept a “market outperform” rating, implying a large upside vs. current levels. Article Title
• Positive Sentiment: Guggenheim nudged its target up to $143 with a “buy” rating, another bullish signal from the sell‑side. Article Title
• Positive Sentiment: Q4 results: EPS of ($0.73) beat consensus ($0.79) and revenue of $57.25M topped estimates; revenue rose ~37% year‑over‑year — evidence of commercial traction for IMCIVREE/setmelanotide. Press Release
• Positive Sentiment: Near‑term clinical and regulatory catalysts: PDUFA goal date for the sNDA in acquired hypothalamic obesity is March 20, 2026, and topline Phase 3/Phase 2 readouts (EMANATE and Japanese cohort) are due in March — binary events that could materially re‑rate the stock. Company Release
• Neutral Sentiment: Full Q4 earnings call transcript and coverage are available for investors wanting color on commercial uptake, launch plans and upcoming milestones. Earnings Transcript
• Negative Sentiment: Needham reduced its price target (from $148 to $139) despite keeping a “buy” rating — mixed analyst signals can create short‑term selling pressure. Ticker Report
• Negative Sentiment: Management flagged significantly higher 2026 non‑GAAP operating expenses ($385M–$415M) as HO launch preparations accelerate — investors may view this as margin dilution and a cash‑burn risk ahead of broader commercialization. Seeking Alpha
• Negative Sentiment: Company still shows a negative net margin and very negative ROE — structural profitability concerns remain until revenue scales and launch economics improve. MarketBeat

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.